vs
FLANIGANS ENTERPRISES INC（BDL）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
FLANIGANS ENTERPRISES INC的季度营收约是REGENXBIO Inc.的1.7倍（$52.6M vs $30.3M），FLANIGANS ENTERPRISES INC净利率更高（1.5% vs -221.3%，领先222.9%），REGENXBIO Inc.同比增速更快（43.0% vs 4.6%），FLANIGANS ENTERPRISES INC自由现金流更多（$4.5M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 4.6%）
Flanigans Enterprises Inc.是一家总部位于美国的餐饮服务企业，主要在佛罗里达州开展业务，旗下拥有Flanigan's海鲜酒吧烧烤连锁休闲餐厅及零售酒类门店，服务客群覆盖当地居民与区域游客，提供平价海鲜、美式家常餐食及各类饮品。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
BDL vs RGNX — 直观对比
营收规模更大
BDL
是对方的1.7倍
$30.3M
营收增速更快
RGNX
高出38.4%
4.6%
净利率更高
BDL
高出222.9%
-221.3%
自由现金流更多
BDL
多$57.3M
$-52.8M
两年增速更快
RGNX
近两年复合增速
4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $52.6M | $30.3M |
| 净利润 | $805.0K | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 3.2% | -190.0% |
| 净利率 | 1.5% | -221.3% |
| 营收同比 | 4.6% | 43.0% |
| 净利润同比 | 1363.6% | -31.2% |
| 每股收益（稀释后） | $0.43 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDLRGNX
| Q4 25 | $52.6M | $30.3M | ||
| Q3 25 | $50.0M | $29.7M | ||
| Q2 25 | $51.9M | $21.4M | ||
| Q1 25 | $53.4M | $89.0M | ||
| Q4 24 | $50.0M | $21.2M | ||
| Q3 24 | $45.4M | $24.2M | ||
| Q2 24 | $48.8M | $22.3M | ||
| Q1 24 | $48.1M | $15.6M |
净利润BDLRGNX
| Q4 25 | $805.0K | $-67.1M | ||
| Q3 25 | $896.0K | $-61.9M | ||
| Q2 25 | $1.4M | $-70.9M | ||
| Q1 25 | $2.7M | $6.1M | ||
| Q4 24 | $55.0K | $-51.2M | ||
| Q3 24 | $184.0K | $-59.6M | ||
| Q2 24 | $1.1M | $-53.0M | ||
| Q1 24 | $1.9M | $-63.3M |
毛利率BDLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率BDLRGNX
| Q4 25 | 3.2% | -190.0% | ||
| Q3 25 | 3.3% | -176.3% | ||
| Q2 25 | 5.5% | -296.3% | ||
| Q1 25 | 6.6% | 13.6% | ||
| Q4 24 | 1.5% | -242.1% | ||
| Q3 24 | 0.7% | -256.6% | ||
| Q2 24 | 4.4% | -251.3% | ||
| Q1 24 | 5.6% | -408.8% |
净利率BDLRGNX
| Q4 25 | 1.5% | -221.3% | ||
| Q3 25 | 1.8% | -208.3% | ||
| Q2 25 | 2.7% | -331.8% | ||
| Q1 25 | 5.0% | 6.8% | ||
| Q4 24 | 0.1% | -241.3% | ||
| Q3 24 | 0.4% | -246.3% | ||
| Q2 24 | 2.3% | -237.7% | ||
| Q1 24 | 4.0% | -405.4% |
每股收益（稀释后）BDLRGNX
| Q4 25 | $0.43 | $-1.30 | ||
| Q3 25 | $0.48 | $-1.20 | ||
| Q2 25 | $0.75 | $-1.38 | ||
| Q1 25 | $1.45 | $0.12 | ||
| Q4 24 | $0.03 | $-0.99 | ||
| Q3 24 | $0.11 | $-1.17 | ||
| Q2 24 | $0.60 | $-1.05 | ||
| Q1 24 | $1.04 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $66.0M | $102.7M |
| 总资产 | $142.1M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDLRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | $732.0K | $323.3M | ||
| Q1 25 | $244.0K | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务BDLRGNX
| Q4 25 | — | — | ||
| Q3 25 | $20.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $22.2M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BDLRGNX
| Q4 25 | $66.0M | $102.7M | ||
| Q3 25 | $65.2M | $161.5M | ||
| Q2 25 | $64.3M | $213.7M | ||
| Q1 25 | $64.0M | $274.2M | ||
| Q4 24 | $61.6M | $259.7M | ||
| Q3 24 | $61.2M | $301.4M | ||
| Q2 24 | $61.3M | $348.3M | ||
| Q1 24 | $61.1M | $390.7M |
总资产BDLRGNX
| Q4 25 | $142.1M | $453.0M | ||
| Q3 25 | $140.6M | $525.2M | ||
| Q2 25 | $140.7M | $581.0M | ||
| Q1 25 | $143.3M | $490.9M | ||
| Q4 24 | $146.9M | $466.0M | ||
| Q3 24 | $142.1M | $519.1M | ||
| Q2 24 | $143.1M | $569.4M | ||
| Q1 24 | $144.4M | $629.2M |
负债/权益比BDLRGNX
| Q4 25 | — | — | ||
| Q3 25 | 0.32× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.36× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.9M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $4.5M | $-52.8M |
| 自由现金流率自由现金流/营收 | 8.5% | -174.0% |
| 资本支出强度资本支出/营收 | 0.9% | 1.7% |
| 现金转化率经营现金流/净利润 | 6.14× | — |
| 过去12个月自由现金流最近4个季度 | $2.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流BDLRGNX
| Q4 25 | $4.9M | $-52.3M | ||
| Q3 25 | $3.4M | $-56.0M | ||
| Q2 25 | $1.4M | $-49.3M | ||
| Q1 25 | $-2.0M | $33.6M | ||
| Q4 24 | $7.7M | $-31.6M | ||
| Q3 24 | — | $-40.5M | ||
| Q2 24 | $3.1M | $-45.5M | ||
| Q1 24 | — | $-55.5M |
自由现金流BDLRGNX
| Q4 25 | $4.5M | $-52.8M | ||
| Q3 25 | $2.4M | $-56.5M | ||
| Q2 25 | $-1.8M | $-49.7M | ||
| Q1 25 | $-3.0M | $32.6M | ||
| Q4 24 | $7.0M | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | $2.2M | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率BDLRGNX
| Q4 25 | 8.5% | -174.0% | ||
| Q3 25 | 4.9% | -189.9% | ||
| Q2 25 | -3.4% | -232.8% | ||
| Q1 25 | -5.5% | 36.6% | ||
| Q4 24 | 13.9% | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | 4.5% | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度BDLRGNX
| Q4 25 | 0.9% | 1.7% | ||
| Q3 25 | 1.9% | 1.7% | ||
| Q2 25 | 6.1% | 1.8% | ||
| Q1 25 | 1.8% | 1.2% | ||
| Q4 24 | 1.5% | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | 1.8% | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率BDLRGNX
| Q4 25 | 6.14× | — | ||
| Q3 25 | 3.75× | — | ||
| Q2 25 | 1.02× | — | ||
| Q1 25 | -0.73× | 5.53× | ||
| Q4 24 | 140.02× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.75× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDL
| Restaurant Food Sales | $30.9M | 59% |
| Package Store Sales | $13.3M | 25% |
| Restaurant Bar Sales | $7.9M | 15% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
